These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2912719)

  • 21. [The clinical and economic impact of generic drugs in the treatment of epilepsy].
    Argumosa A; Herranz JL
    Rev Neurol; 2005 Jul 1-15; 41(1):45-9. PubMed ID: 15999330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjustment of carbamazepine dose to offset the effects of the interaction with remacemide hydrochloride in a double-blind, multicentre, add-on drug trial (CR2237) in refractory epilepsy.
    Mawer GE; Jamieson V; Lucas SB; Wild JM
    Epilepsia; 1999 Feb; 40(2):190-6. PubMed ID: 9952266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of metabolic parameters of carbamazepine in the therapeutic monitoring of Tunisian patients with epilepsy.
    Chbili C; Hassine A; Ben Amor S; Nouira M; Ben Ammou S; Saguem S
    Rev Neurol (Paris); 2016; 172(4-5):313-7. PubMed ID: 27062293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations.
    Garnett WR; Gilbert TD; O'Connor P
    Clin Ther; 2005 Jul; 27(7):1092-103. PubMed ID: 16154489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for carbamazepine elevation and toxicity following epilepsy surgery.
    Hiremath GK; Kotagal P; Bingaman W; Hovinga C; Wyllie E; Morris H; Nelson D
    Seizure; 2005 Jul; 14(5):312-7. PubMed ID: 15876544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.
    Patsalos PN
    Br J Clin Pharmacol; 1990 May; 29(5):574-7. PubMed ID: 2350535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine.
    Bialer M; Yacobi A; Moros D; Levitt B; Houle JM; Munsaka MS
    Epilepsia; 1998 May; 39(5):513-9. PubMed ID: 9596204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, placebo-controlled, double-blind study of efficacy of a new form of carbamazepine (Carbatrol) in refractory epileptic patients.
    Sobaniec W; Kułak W; Smigielska-Kuzia J; Boćkowski L; Majkowski J; Jedrzejczak J
    Pol J Pharmacol; 2004; 56(2):195-201. PubMed ID: 15156070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
    Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
    J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of interaction of gabapentin with carbamazepine or valproate.
    Radulovic LL; Wilder BJ; Leppik IE; Bockbrader HN; Chang T; Posvar EL; Sedman AJ; Uthman BM; Erdman GR
    Epilepsia; 1994; 35(1):155-61. PubMed ID: 8112239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?
    Houtkooper MA; Lammertsma A; Meyer JW; Goedhart DM; Meinardi H; van Oorschot CA; Blom GF; Höppener RJ; Hulsman JA
    Epilepsia; 1987; 28(6):693-8. PubMed ID: 3319537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative drug monitoring of carbamazepin suspension (TroyaPharm) and Tegretol syrup (Ciba Geigy) in epileptic children.
    Peytchev L; Chakova L
    Folia Med (Plovdiv); 1998; 40(4):29-33. PubMed ID: 10371796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients.
    El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H
    J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carbamazepine withdrawal: effects of taper rate on seizure frequency.
    Malow BA; Blaxton TA; Stertz B; Theodore WH
    Neurology; 1993 Nov; 43(11):2280-4. PubMed ID: 8232943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carbamazepine therapy and long-term prognosis in epilepsy of childhood.
    Okuno T; Ito M; Nakano S; Hattori H; Fujii T; Go T; Mikawa H
    Epilepsia; 1989; 30(1):57-61. PubMed ID: 2912717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacology of chewable versus regular carbamazepine in chronically treated children with epilepsy.
    Camfield P; Hwang P; Camfield C; Fraser A; Soldin S; al-Quadah AK
    Can J Neurol Sci; 1992 May; 19(2):204-7. PubMed ID: 1623447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Carbamazepine: a clinical biopharmaceutical study.
    Dam M; Christiansen J; Kristensen CB; Helles A; Jaegerskou A; Schmiegelow M
    Eur J Clin Pharmacol; 1981; 20(1):59-64. PubMed ID: 7308274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children.
    Hartley R; Forsythe WI; McLain B; Ng PC; Lucock MD
    Clin Pharmacokinet; 1991 Mar; 20(3):237-46. PubMed ID: 2025982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: a blinded, randomized study.
    El-Mallakh RS; Salem MR; Chopra AS; Mickus GJ; Penagaluri P
    Int Clin Psychopharmacol; 2009 May; 24(3):145-9. PubMed ID: 19367153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of absorption rate and bioavailability of two brands of carbamazepine.
    Revankar SN; Desai ND; Bhatt AD; Bolar HV; Sane SP; Gupta C; Kamat DV
    J Assoc Physicians India; 1999 Jul; 47(7):699-702. PubMed ID: 10778590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.